Key result
Bortezomib treatment in a 56-year-old woman with multiple myeloma was associated with severe heart failure, including an LVEF of 25%, severe mitral regurgitation, and pericardial effusion.
Case Report (n=1)
Bortezomib treatment can induce severe cardiotoxicity, including heart failure with reduced ejection fraction, pericardial effusion, and mitral regurgitation, independent of prior anthracycline exposure.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to possible bortezomib cardiotoxicity; leaves open incidence, causality, and monitoring needs in myeloma.
Bockorny et al. (2012) conducted a case report in Multiple Myeloma and Heart Failure (n=1). Bortezomib/dexamethasone-based chemotherapy was evaluated on Development of heart failure (LVEF 25%, severe eccentric mitral regurgitation, and moderate pericardial effusion). Bortezomib treatment in a 56-year-old woman with multiple myeloma was associated with severe heart failure, including an LVEF of 25%, severe mitral regurgitation, and pericardial effusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: